Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

Executive Summary

• Fennec Pharmaceuticals announced an underwritten registered public offering of its common shares, with a 30‑day over‑allotment option for up to an additional 15% of the shares sold.
• Net proceeds are earmarked first to repurchase and redeem certain indebtedness; any remaining funds will be used for working capital and general corporate purposes.
• Piper Sandler & Co. and Craig‑Hallum Capital Group LLC are acting as joint book‑running managers for the offering.

Key Details

• Offering Structure: Common shares offered pursuant to an effective SEC registration statement; underwriters granted a 30‑day option to purchase up to an additional 15% of the shares sold in the base offering.
• Use of Proceeds:
• Primary: Repurchase and redemption of certain indebtedness.
• Secondary: Working capital and general corporate purposes.
• Book‑Running Managers: Piper Sandder & Co. (joint book‑running manager) and Craig‑Hallum Capital Group LLC (joint book‑running manager).
• Availability of Prospectus: Preliminary prospectus supplement and accompanying prospectus to be filed with the SEC; accessible via the SEC website or directly from the underwriters’ prospectus departments (contact details provided).
• Regulatory Notes: The press release does not constitute an offer or solicitation where such would be unlawful; the shares will not be offered or sold in Canada or to Canadian residents.

Notable Quotes

(No direct quotes were included in the release.)